

Fact Sheet | October 2023

Viroclinics-DDL Polio Laboratory for Research and Services in support of (Pre) Clinical Trials

With poliovirus type 2 and type 3 officially declared eradicated in 2015 and 2019, polio is on the brink of eradication. Only poliovirus type 1 remains at large.

To minimize the poliovirus facility associated risk after eradication of wildtype polioviruses and sequential cessation of oral polio vaccine use, the WHO has installed a Global Action Plan (GAP IV). Under GAP IV, only facilities certified as a Polio essential facility (PEF) maintain the ability to work with (potentially) infectious polio material.

Viroclinics-DDL is proud to announce it has been granted with the Certificate of Participation to operate as a PEF and it is now further positioning as a Polio Laboratory for Research and Services in support of (Pre) Clinical Trials. With its 5000 ft² dedicated GAP IV compliant polio facility Viroclinics-DDL can safeguard the proper handling of polio research which will contribute to the eradication of polio.

Early-stage research, preclinical and clinical diagnostics services are offered for vaccine manufacturers, research and diagnostic institutes and companies in need to screen their samples for the (potential) presence of poliovirus. A broad array of samples including live poliovirus, serum and stool samples can be analyzed.



About Viroclinics-DDL, a Cerba Research Company

At Cerba Research we provide world-class (pre) clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of human-centric healthcare by transforming research, and advancing health together.

We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of healthcare, by transforming research, and advancing health together.

18,000 ft² Preclinical Laboratory Area



We offer the following services

Virus titration/quantification using fully validated CCID50 protocols

Quantitative virus detection using fully validated qPCR protocols

Neurovirulence testing through a certified and validated assay in transgenic mice (PVR21)

Virus neutralization fully validated on 9 strains (Wildtype, Sabin and S19)

Several species are available for preclinical testing

Mutational analysis of (whole genome) poliovirus through Deep sequencing (NGS)

Storage of samples and (vaccine) virus stocks

Contact Information

Vaccine development services

<https://cerbaresearch.com/therapeutic-scientific-expertise/vaccine-development/>